333 related articles for article (PubMed ID: 32599834)
1. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.
Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
Anthony C; Mladkova-Suchy N; Adamson DC
Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
[No Abstract] [Full Text] [Related]
5. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
Rose SD; Aghi MK
Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
[No Abstract] [Full Text] [Related]
6. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
Gerstner ER; Emblem KE; Sorensen GA
Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087
[TBL] [Abstract][Full Text] [Related]
7. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK; Engelhard HH; Lakka SS
Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in glioblastoma multiforme: navigating the maze.
Linkous AG; Yazlovitskaya EM
Anticancer Agents Med Chem; 2011 Oct; 11(8):712-8. PubMed ID: 21707499
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic inhibition in high-grade gliomas: past, present and future.
Jo J; Schiff D; Purow B
Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo.
Grodzik M; Sawosz E; Wierzbicki M; Orlowski P; Hotowy A; Niemiec T; Szmidt M; Mitura K; Chwalibog A
Int J Nanomedicine; 2011; 6():3041-8. PubMed ID: 22162660
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
12. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
de Boüard S; Guillamo JS
Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
14. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
[TBL] [Abstract][Full Text] [Related]
15. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.
Gao H; Xiong Y; Zhang S; Yang Z; Cao S; Jiang X
Mol Pharm; 2014 Mar; 11(3):1042-52. PubMed ID: 24521297
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.
Lombardi G; Pambuku A; Bellu L; Farina M; Della Puppa A; Denaro L; Zagonel V
Crit Rev Oncol Hematol; 2017 Mar; 111():94-102. PubMed ID: 28259301
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
Pellerino A; Bruno F; Soffietti R; Rudà R
Curr Oncol Rep; 2023 Jul; 25(7):777-785. PubMed ID: 37071295
[TBL] [Abstract][Full Text] [Related]
19. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
20. Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far.
Clavreul A; Pourbaghi-Masouleh M; Roger E; Menei P
Int J Nanomedicine; 2019; 14():2497-2513. PubMed ID: 31040671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
